Fandrey J K, Jelkmann W E
Physiologisches Institut I, Rheinischen Friedrich-Wilhelms-Universität Bonn.
Z Gesamte Inn Med. 1992 Jun;47(6):231-8.
The renal glycoprotein hormone erythropoietin is an essential growth factor for the erythrocytic progenitors in the bone marrow. Erythropoietin deficiency is the main cause of the anemia in chronic renal failure. Genetical engineering has made it possible to produce recombinant human erythropoietin (rhu-Epo) in CHO cell cultures as a pharmaceutical compound. Endogenous and recombinant erythropoietin are similar with respect to their biological and chemical properties (M(r) 30,400 Da, protein content 60%, 165 amino acids, 4 carbohydrate side chains). With few side-effects, rhu-Epo corrects the anemia of predialysis and dialysis renal failure patients. In addition, rhu-Epo treatment may reduce the need for blood transfusion in other types of anemias, including those of rheumatoid arthritis, AIDS, malignant diseases and major surgical procedures. However, rhu-Epo has not been approved as yet for treatment of non-renal anemias in Germany.
肾脏糖蛋白激素促红细胞生成素是骨髓中红细胞祖细胞的一种重要生长因子。促红细胞生成素缺乏是慢性肾衰竭贫血的主要原因。基因工程使得在CHO细胞培养物中生产重组人促红细胞生成素（rhu-Epo）作为一种药物化合物成为可能。内源性和重组促红细胞生成素在生物学和化学性质方面相似（分子量30,400道尔顿，蛋白质含量60%，165个氨基酸，4条碳水化合物侧链）。rhu-Epo副作用较少，可纠正透析前和透析肾衰竭患者的贫血。此外，rhu-Epo治疗可能减少其他类型贫血患者的输血需求，包括类风湿性关节炎、艾滋病、恶性疾病和大手术患者的贫血。然而，在德国，rhu-Epo尚未被批准用于治疗非肾性贫血。
